Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SGA306
- Development stage
- Preclinical
- Lead developer
- BMG Pharma
- Administration
- Intradermal
01
Overview
SGA306 is an injectable dermal filler being developed by BMG Pharma for aesthetic medicine, specifically for lip augmentation. Currently in the preclinical stage, the product is designed to be administered via injection to provide volume and structural enhancement to the lips. BMG Pharma's expertise in hyaluronic acid and polymer science suggests that SGA306 is likely a biocompatible gel-based filler intended for minimally invasive cosmetic procedures.
- Other names
- SGA306 Filler LipsSGA-306 Filler LipsSGA 306 Filler Lips
Beyond the preview
Go deeper on SGA306.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SGA306.